Phthalimide

Phthalimide

SCHEMBL932346

O=C1NC(=O)c2ccccc21.[N]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.94
CASP7 P55210 3/20 0.75
CASP3 P42574 2/20 0.75
CASP6 P55212 2/20 0.75
CASP8 Q14790 2/20 0.75
CASP2 P42575 1/20 0.75
PARP1 P09874 4/20 0.56
PDGFRA P16234 1/20 0.56
FER P16591 1/20 0.56
LTK P29376 1/20 0.56
CDK8 P49336 1/20 0.56
ACVR1 Q04771 1/20 0.56
LRRK2 Q5S007 1/20 0.56
DYRK1B Q9Y463 1/20 0.56
MAPK1 P28482 4/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HSD17B10 Q99714 1/20 0.52
MAOA P21397 5/20 0.50
MAOB P27338 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalimide SCHEMBL7771670 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL64 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL10192661 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL11040503 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL29366030 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL30125197 0.97 GSK3B (1.00) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL165345 0.94 GSK3B (0.94) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL228977 0.94 GSK3B (0.94) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL9421750 0.94 GSK3B (0.94) GSK3BCASP7CASP3CASP6CASP8
Phthalimide SCHEMBL1205294 0.94 GSK3B (0.94) GSK3BCASP7CASP3CASP6CASP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637667-B2 Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives LEGOCHEM BIOSCIENCE LTD. (KR) 2014-01-28 US claimed
US-20120108808-A1 METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES LEGOCHEM BIOSCIENCE LTD. (KR) 2012-05-03 US claimed
WO-2011005028-A2 METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES LEGOCHEM BIOSCIENCE LTD. (KR) 2011-01-13 WO claimed
US-20090029979-A1 5-HTX MODULATORS BIO-MEDISINSK INNOVASJON AS (NO) 2009-01-29 US claimed
EP-1902044-A1 5-HTX MODULATORS Bio Medisinsk Innovasjon AS (NO) 2008-03-26 EP claimed
WO-2007007072-A1 5-HTX MODULATORS BIO-MEDISINSK INNOVASJON AS (NO) 2007-01-18 WO claimed
CN-114717582-B Method for preparing theophylline derivatives by green electrochemical coupling 云南大学 2023-09-19 CN disclosed
EP-4217412-A1 WASTE MITIGATION METHODS AND MATERIALS Finite Research Ltd (GB) 2023-08-02 EP disclosed
CN-114717582-A Method for preparing theophylline derivatives through green electrochemical coupling 云南大学 2022-07-08 CN disclosed
WO-2022023916-A1 WASTE MITIGATION METHODS AND MATERIALS LI, Zhenzhen (CN) 2022-02-03 WO disclosed
US-20220025119-A1 WASTE MITIGATION METHODS AND MATERIALS LI SHENSHEN (US) 2022-01-27 US disclosed
US-8637667-B2 Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives LEGOCHEM BIOSCIENCE LTD. (KR) 2014-01-28 US disclosed
US-20120108808-A1 METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES LEGOCHEM BIOSCIENCE LTD. (KR) 2012-05-03 US disclosed
US-6716840-B2 AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES CHIRON CORPORATION 2004-04-06 US disclosed
US-20040024211-A1 Novel guanidino compounds CHIRON CORPORATION 2004-02-05 US disclosed
EP-1385823-A1 NOVEL GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2004-02-04 EP disclosed
US-20020193595-A1 Novel guanidino compounds CHU DANIEL (US) 2002-12-19 US disclosed
WO-2002081443-A1 NOVEL GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2002-10-17 WO disclosed
US-6187931-B1 Process for making fluorophthalimides ALBEMARLE CORPORATION 2001-02-13 US disclosed
US-4106940-A N-ALKYLPHTHALIMIDE DERIVATIVE OIL FORMER AGFA-GEVAERT, A.G. (DE) 1978-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029979-A1 5-HTX MODULATORS HTR7, HTR5A, HTR2C GSK3B 552/4885CASP7 1153/4885CASP3 2197/4885
US-20040024211-A1 Novel guanidino compounds MC4R, MC5R, MC3R GSK3B 1987/4885CASP7 2801/4885CASP3 3584/4885
US-20020193595-A1 Novel guanidino compounds MC4R, MC5R, MC3R GSK3B 2013/4885CASP7 2728/4885CASP3 3619/4885
US-20120108808-A1 METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES F2, F11, F5 GSK3B 2373/4885CASP7 1557/4885CASP3 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.